Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma. Issue 39 (22nd September 2015)

• Record Type: Journal Article
• Authors: Marconato, L.; Stefanello, D.; Sabattini, S.; Comazzi, S.; Riondato, F.; Laganga, P.; Frayssinet, P.; Pizzoni, S.; Rouquet, N.; Aresu, L.
• Is Part Of: Vaccine. Volume 33:Issue 39(2015)
• Page Start: 5080
• Page End: 5086
• Publication Date: 2015-09-22
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.08.017
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Canine indolent B-cell lymphoma of advanced clinical stage is an incurable disease.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Autologous heat shock proteins induced immunity against DLBCL in a canine trial.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Chemo-immunotherapy improved time to progression in dogs with indolent lymphoma.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Dogs mounting an immune response lived significantly longer.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">There were no vaccine-related side effects.</p> </list-item> </list> </p> </sec> </abstract>